Tag: Biotech
The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030
Report features an extensive study on the contract service providers within the biopharmaceutical industry.
Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug
Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain.
Biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~8%, till 2030
Roots Analysis has done a detailed study on Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
The biopharmaceutical contract manufacturing market - Roots Analysis
Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production
The “Cell Therapy Manufacturing Market (3rd Edition), 2019-2030
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies.
More than 100 industry players and over 60 non-industry players currently claim to manufacture different types of cell therapies, either for in-house requirements or on contract basis
Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers .
The cell therapy manufacturing market is projected to grow at an annualized rate of >16.5%, till 2030
Roots Analysis has done a detailed study on Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030, covering various important aspects of the industry and identifying key future growth opportunities.
The cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030, predicts Roots Analysis
Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise.
